First Trust Expanded Technology ETF (ARCA: XPND)

Latest News for First Trust Expanded Technology ETF (ARCA:XPND)

First Trust Expanded Technology ETF

Key witness Michael Cohen testified in the hush money criminal trial against former President Donald Trump on Monday, sharing details of his role in paying to get rid of several stories that could harm Trump&#8217;s chances in <a href="https://www.benzinga.com/general/politics/24/05/38794046/michael-cohen-says-he-never-wanted-to-go-into-law-was-offered-375k-to-work-for-donald-trump-goin">the 2016 election.</a>
What Happened: On Monday, Cohen testified to his involvement in making payments to several parties in<a href="https://www.benzinga.com/general/politics/24/04/38251447/trump-hush-money-trial-preview-key-witnesses-2024-campaign-impact-prison-time-trump-could-face-i"> a hush money scheme</a> that could help eliminate bad stories that would hurt Trump in the election from being made public.
Trump faces criminal charges related to falsifying business records for the alleged hush money payments.
Cohen said that he was called by Trump on his bodyguard Keith Schiller's phone angry that a story by the Wall Street Journal was published about payments made by American Media to Karen McDougal, a former Playboy model who sold a story alleging an affair with Trump.
Trump's former lawyer recalled talking to David Pecker and Hope Hicks and was told "to get control over the release of that article,&#8221; <a href="https://www.nbcnews.com/politics/donald-trump/live-blog/trump-hush-money-trial-day-16-michael-cohen-live-updates-rcna151898">according </a>to NBC News. 
Cohen said a $130,000 payment he wired to lawyer Keith Davidson on Oct. 27, 2016 was marked "retainer," but was actually part of the hush money agreement with Stormy Daniels, who was represented by Davidson.
"It was in order to pay Stormy Daniels to execute the NDA and to obtain the story."
Cohen said he would not make the payment without getting approval from Trump because he wanted to make sure he would be paid back.
The former Trump lawyer testified Trump told him that he was advised by some friends and "very smart people" to just pay the money.
"There's no reason to keep this thing out there. Just do it," Cohen recalled Trump saying.
Cohen testified Trump Organization Chief Financial Officer Allen Weisselberg told him he would be paid back for making the payment to Daniels.
"We'll make sure you get paid back," Cohen said Weisselberg told him. "Don't worry Michael. You will get paid back."
Cohen said he was told to try and delay payment until after the election. The thought was that if Trump won the election, the story wouldn't matter and if Trump lost he wouldn't care if the story became public.
These details from the prosecution could point to the role the story had in influencing the 2016 presidential election as alleged.
Cohen said Trump told him previously to "take care of it," when asked about the Daniels story.
The former Trump lawyer testified to helping facilitate payment for the life rights to McDougal's story.
"What I was doing, I was doing at the direction of and for the benefit of Mr. Trump."
An audio clip was played Monday that featured Trump, Cohen and Weisselberg discussing a payment. Cohen said the conversation he recorded was about purchasing McDougal's life rights and was the only conversation with Trump he recorded.
Related Link: <a href="https://www.benzinga.com/general/politics/24/05/38749159/stormy-daniels-says-she-never-asked-for-money-in-trump-hush-money-case-former-president-declares">Stormy Daniels Says She &#8216;Never Asked For Money&#8217; In Trump Hush Money Case, Former President Declares He&#8217;s &#8216;So Innocent&#8217;</a>
What Else Happened: Cohen detailed banking documents and the execution of the deal with Daniels on Monday in detail for the jury.
Cohen testified that after Trump won the 2016 election, he was out of a job. Cohen said he pitched becoming the personal attorney for Trump, but wasn't hired.
"My service was no longer necessary as I was special counsel to Mr. Trump, and he was president-elect," Cohen said.
Cohen said he didn't want the role of Chief of Staff but would've liked to have been offered the position.
"I didn't want the role, I didn't believe that the role was right for me or that I was even competent to be chief of staff. I just wanted my name to have been included. It was more about my ego than anything."
Cohen also shared that he saw his bonus slashed at the end of 2016 and was angry and hurt.
"I actually had to do a double-take."
Cohen is expected to be on the stand again on Tuesday and will be one of the last witnesses from the prosecution in the multi-week trial.
Read Next: <a href="https://www.benzinga.com/general/politics/24/05/38626165/hope-hicks-testifies-on-trumps-ex-lawyer-michael-cohens-mr-fix-it-moniker-only-because-he-broke-">Hope Hicks Testifies On Trump&#8217;s Ex-Lawyer Michael Cohen&#8217;s &#8216;Mr. Fix It&#8217; Moniker: &#8216;Only Because He Broke It First&#8217;</a>
Photo: a katz via Shutterstock

Politics

Legal

Trump's Erstwhile Lawyer Testifies To Former President's Involvement In Hush Money Payment: 'Don't Worry Michael, You Will Get Paid Back'

News

Guidance

American Healthcare REIT Says FY24 Guidance Remains Unchanged; Sees NFFO Per Share Of $1.18-$1.24, Est $1.21

MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) has outperformed the market over the past 10 years by 17.17% on an annualized basis producing an average annual return of 27.92%. Currently, MSCI has a market capitalization of $38.47 billion. 
Buying $1000 In MSCI: If an investor had bought $1000 of MSCI stock 10 years ago, it would be worth $11,409.07 today based on a price of $485.57 for MSCI at the time of writing.
<h3>MSCI's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715635817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MSCI

$1000 Invested In MSCI 10 Years Ago Would Be Worth This Much Today

PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) has outperformed the market over the past 10 years by 9.37% on an annualized basis producing an average annual return of 20.13%. Currently, PulteGroup has a market capitalization of $24.48 billion. 
Buying $100 In PHM: If an investor had bought $100 of PHM stock 10 years ago, it would be worth $620.36 today based on a price of $116.38 for PHM at the time of writing.
<h3>PulteGroup's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715635812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today

American Healthcares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) reported quarterly earnings of $0.30 per share which met the analyst consensus estimate. This is a 3.23 percent decrease over earnings of $0.31 per share from the same period last year.

Earnings

American Healthcares Q1 2024 NAREIT FFO per common share $0.30, Inline

Blank Check Company EVe Mobility Acquisition Reports Extension Of Deadline To Complete Initial Business Combination From May 17 To June 17

LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) reported quarterly losses of $(0.35) per share. This is a 250 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $29.101 million which beat the analyst consensus estimate of $27.675 million by 5.15 percent. This is a 27.56 percent increase over sales of $22.814 million the same period last year.

Earnings Beats

LUXH

LuxUrban Hotels Q1 2024 GAAP EPS $(0.35) Down From $(0.10) YoY, Sales $29.101M Beat $27.675M Estimate

While investor interest was strong, given the continued positive performance of the Company&#39;s underlying business and anticipated trajectory following its recent entry to the U.S. gaming market earlier this year, the Company&#39;s Board of Directors believes it is in the best interests of its stakeholders to delay the offering at this time and will continue to monitor the timing for the proposed offering.

IPOs

iGaming Company Games Global Postpones IPO

The common shares are expected to be offered by Novelis&#39; sole shareholder (a wholly owned subsidiary of Hindalco Industries Limited). Novelis will not receive any proceeds from the sale of common shares by its sole shareholder.
Novelis is a subsidiary of Hindalco Industries Limited, a&nbsp;metals flagship company of the Aditya Birla Group, a multinational conglomerate based in&nbsp;Mumbai.

Novelis Files Registration Statement For Proposed IPO; Intends To List Its Common Shares On NYSE Under Ticker Symbol 'NVL'

Paysafe Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) reported its first-quarter financial results after the bell Monday. Here's a <a href="https://www.benzinga.com/pressreleases/24/05/b38800111/paysafe-reports-first-quarter-2024-results-reaffirms-full-year-outlook">look at the highlights. </a>
The Details: Paysafe reported first-quarter adjusted earnings of 57 cents per share, beating the 10 cent analyst consensus estimate.
Quarterly sales came in at $417.7 million, reflecting a 7% growth in total payment volume and beating the $408.25 million estimate.
Revenue from the Merchant Solutions segment increased 11%, reflecting double-digit growth in e-commerce as well as growth from small and medium-sized businesses driven by initiatives to expand sales capabilities and optimize the portfolio. 
Revenue from the Digital Wallets segment increased 5% as reported and 4% in constant currency, reflecting growth from gambling merchants as well as ongoing initiatives related to product and consumer engagement.
&#8220;We are off to a great start this year, delivering 8% year-over-year revenue growth in the first quarter, reinforcing that our strategic initiatives and associated investments are driving momentum in the business and setting us up for long-term success. We remain confident in our financial outlook for this year, which reflects stronger underlying revenue performance, anchored by improved operational execution,&#8221; Bruce Lowthers, CEO of Paysafe, said.
Outlook:  Paysafe reaffirmed its full-year 2024 revenue guidance of between $1.688 billion and $1.712 billion, versus the $1.7 billion analyst consensus estimate.
PSFE Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Paysafe shares are up 7.21% after-hours at $16.80 at the time of publication Monday.
Related News: <a href="https://www.benzinga.com/news/24/05/38795608/gamestop-leads-roaring-rally-whats-going-on-with-meme-stocks">GameStop Leads Roaring Rally: What&#8217;s Going On With Meme Stocks?</a>
Photo: Buffik from Pixabay

After-Hours Center

Movers

PSFE

Paysafe Stock Climbs On Q1 Results: Here's Why

FBRX

CORRECTION: Forte Biosciences Q1 GAAP EPS $(0.16) Beats $(0.17) Estimate

CHCI

Comstock Inks Four New Leases At The Hartford Building, Virginia

Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.78) by 8.97 percent.

Earnings Misses

TSBX

Turnstone Biologics Q1 EPS $(0.85) Misses $(0.78) Estimate

Guardion Health Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHSI#NASDAQ">GHSI</a>) reported quarterly losses of $(3.71) per share which missed the analyst consensus estimate of $(0.88) by 321.59 percent. This is a 983.33 percent decrease over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $3.00 million which missed the analyst consensus estimate of $3.12 million by 3.86 percent. This is a 5.85 percent decrease over sales of $3.19 million the same period last year.

GHSI

Guardion Health Sciences Q1 EPS $(3.71) Misses $(0.88) Estimate, Sales $3.00M Miss $3.12M Estimate

Norman Fan&nbsp;will assume the interim position of overseeing the financial and reporting functions of the Company.&nbsp;

Management

HSAI

Hesai Group Louis T. Hsieh Has Resigned From His Positions As Global CFO And Board Director For Personal And Family Reasons, Effective Today

HBNC

Horizon Bancorp Appoints John Stewart As CFO

4 analysts have shared their evaluations of Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.25, a high estimate of $17.00, and a low estimate of $14.00. Observing a 12.96% increase, the current average has risen from the previous average price target of $13.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1715634070_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Fulcrum Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fulcrum Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Fulcrum Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Fulcrum Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fulcrum Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FULC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fulcrum Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Fulcrum Therapeutics Better</h2>
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
<h3>Breaking Down Fulcrum Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Fulcrum Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 27.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Fulcrum Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2842.25%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Fulcrum Therapeutics's ROE excels beyond industry benchmarks, reaching -10.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.23%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Fulcrum Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

FULC

Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)

10 analysts have shared their evaluations of Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Paycor HCM, revealing an average target of $28.2, a high estimate of $42.00, and a low estimate of $19.00. This current average has increased by 9.05% from the previous average price target of $25.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1715634063_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Paycor HCM is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Bhavin Shah</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Mark Marcon</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Paycor HCM. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Paycor HCM compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Paycor HCM's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Paycor HCM's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PYCR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Paycor HCM analyst ratings.</a>
<h2>Delving into Paycor HCM's Background</h2>
Paycor HCM provides payroll and human capital management solutions to small and midsize clients in the United States via a software-as-a-service model. Alongside core payroll functionality, the firm's platform offers a suite of HCM solutions including talent management and time and attendance software, third-party integration capabilities, and industry-specific configurations. The firm targets customers with 10-1,000 employees and had over 30,000 customers as of June 2023.
<h3>Paycor HCM: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Paycor HCM's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.81% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Paycor HCM's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.48%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Paycor HCM's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.22%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Paycor HCM's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PYCR

Analyst Scoreboard: 10 Ratings For Paycor HCM

Throughout the last three months, 4 analysts have evaluated Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.0, a high estimate of $13.50, and a low estimate of $11.00. This current average has increased by 20.0% from the previous average price target of $10.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715634055_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Lifetime Brands's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lifetime Brands. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lifetime Brands compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Lifetime Brands's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Lifetime Brands's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LCUT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lifetime Brands analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Lifetime Brands</h2>
Lifetime Brands Inc is a U.S. based company that designs, sources, and sells branded kitchenware, tableware, and other products used in the home and markets its products under brands such as Farberware, KitchenAid, Mikasa, and others. The company markets and sells its products principally on a wholesale basis to retailers. It also markets and sells a limited selection of its products directly to consumers through its Pfaltzgraff, Mikasa, Fred, and Friends, Built NY, and others. Its products include kitchen tools, gadgets, cutlery, dinnerware, and glassware. The segments of the company are the U.S. and International. It derives a majority of its revenue from the U.S. segment. The company derives maximum revenue from Kitchenware products.
<h3>Unraveling the Financial Story of Lifetime Brands</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Lifetime Brands's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -1.88%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Lifetime Brands's net margin excels beyond industry benchmarks, reaching 1.33%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.18%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Lifetime Brands's ROA stands out, surpassing industry averages. With an impressive ROA of 0.4%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Lifetime Brands's debt-to-equity ratio stands notably higher than the industry average, reaching 1.23. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LCUT

The Analyst Landscape: 4 Takes On Lifetime Brands

Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.4, along with a high estimate of $18.00 and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 24.9% from the previous average price target of $12.33.
<img src="https://www.benzinga.com/files/images/story/2024/1715634032_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into CareDx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into CareDx's Background</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>Key Indicators: CareDx's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, CareDx faced challenges, resulting in a decline of approximately -20.41% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin is impressive, surpassing industry averages. With a net margin of -180.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CareDx's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -36.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): CareDx's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -24.4%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.13, CareDx adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDNA

Navigating 5 Analyst Ratings For CareDx

First Trust Expanded Technology ETF declares $0.0061 dividend

Equity Outlook: Earnings Step Back Into The Market Spotlight

April 2024 Perspective

Tailwinds In Tech

The Outlook For The U.S. Economy Is Bullish

Why The Market Rally May Still Have Room To Run, Even If Tech Stocks Falter

The Perils Of Owning The Wrong Tech Stocks

Is There A Tech Bubble? Our Current Tech Positioning

Quality Is Now A Momentum Trade

Big Energy

AAPL

ACTV

ACWI

ACWV

AFMC

AFSM

AFTY

AIRR

AMZN

ANEW

ARKF

ARKK

ARKQ

ARKW

ARKX

ASET

ASHR

ASHS

AVUV

BAPR

BBCA

BBEU

BBJP

BLCN

BLOK

BOIL

BOTZ

BTEK

CBON

CCRV

CHIM

CHIQ

CHIX

CIBR

CLOU

CMDY

CNRG

CNXT

CNYA

COMB

COMT

CQQQ

CRAK

CRBN

CXSE

DAPP

DBEU

DBEZ

DBJP

DGRO

DJCB

DTEC

DUSL

DWLD

DXJS

ECNS

ESGG

ESPO

EUDG

EUDV

EURL

EUSC

EWJV

FAAR

FCOM

FENY

FEUZ

FIDU

FILL

FINX

FITE

FIVG

FLCA

FLCH

FLEE

FLEU

FLHK

FLJH

FLJP

FLTW

FNDB

FNDX

FNGS

FPXE

FTEC

FTGC

FTXL

FTXN

FTXR

GAMR

GINN

GLOF

GOOG

GOOGL

GRNTF

GSEU

GSJY

HACK

HDRO

HEDJ

HERO

HEWJ

HEZU

IDAT

IDGT

IDRV

IEMG

IETC

IEUR

IEUS

IGPT

IHAK

ILCV

ILDR

INDA

INTC

IRBO

ITEQ

IUSV

IVOO

IVOV

IWFH

IZRL

JJETF

JPXN

KALL

KARS